Zim Laboratories Ltd
Zim Laboratories Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
The company expects a 25%-30% CAGR growth over the next few years, driven mainly by fast-growing NIP (Novel Innovative Products) and OTF (Orally Thin Film) products. ZIM expects a growth rate of 25% to 30% CAGR in revenues over the next few years, driven largely by NIP and OTF products expanding to 30%-40% of total turnover by FY26-FY27.
From Zim Laboratories Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company expects a 25%-30% CAGR growth over the next few years, driven mainly by fast-growing NIP (Novel Innovative Products) and OTF (Orally Thin Film) products.
- NIP and OTF currently contribute about 16%-19% of sales, projected to increase to 30%-40% in the coming years, potentially reaching 50% over time.
- Growth will come from regulated markets (Europe, Australia, UK) as well as emerging and RoW (Rest of World) markets.
- Base/legacy business is expected to stabilize with nominal growth, recovering to past levels after recent challenges.
2 more points from Zim Laboratories Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Zim Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Major CapEx has already been completed, focusing on upgradation and technology improvement going forward (Page 21, 24).
- No further major CapEx or new big projects planned; future CapEx limited to facility upgrades (Page 21, 24).
- Capacity utilization currently low; newly built capacity will be better utilized once marketing authorizations (MAs) are received (Page 20, 24).
- Strategic focus on expanding geographical footprint and entering regulated markets with NIP and OTF products; investments aligned accordingly (Page 23, 18).
2 more points from Zim Laboratories Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Zim Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- There was a significant order from the Government of Maharashtra worth around INR 20 crores that got deferred due to the election year in FY25.
- This order did not get deferred to the next year, impacting the domestic revenue temporarily.
- The legacy business faced some delays related to currency issues with a large client, which have now been resolved.
- The company expects the legacy business orders to come back to previous levels with nominal growth.
- Production schedules for new products depend largely on marketing partners' readiness, with manufacturing expected to start once orders are received.
2 more points from Zim Laboratories Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Zim Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹105 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zim Laboratories's management said in earlier quarters
Arthneeti Pro · Annual
Zim Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Zim Laboratories Ltd Q4 FY25 results?
The company expects a 25%-30% CAGR growth over the next few years, driven mainly by fast-growing NIP (Novel Innovative Products) and OTF (Orally Thin Film) products. ZIM expects a growth rate of 25% to 30% CAGR in revenues over the next few years, driven largely by NIP and OTF products expanding to 30%-40% of total turnover by FY26-FY27.
What is Zim Laboratories Ltd share price analysis?
Zim Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 141.2 with a market cap of ₹614 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zim Laboratories Ltd planning capital expenditure?
Major CapEx has already been completed, focusing on upgradation and technology improvement going forward (Page 21, 24).
Keep Zim Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.